43 results on '"Samaniego, Felipe"'
Search Results
2. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients
3. Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus‐infected patients
4. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
5. Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma
6. Frontline antibiotic therapy for early‐stage Helicobacter pylori ‐negative gastric MALT lymphoma
7. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma
8. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
9. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
10. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
11. Clinicopathologic characteristics and outcomes of transformed diffuse largeB‐cell lymphoma in hepatitisCvirus‐infected patients
12. The oncologic burden of hepatitis C virus infection: A clinical perspective
13. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
14. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
15. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study
16. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
17. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model
18. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma
19. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
20. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
21. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
22. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
23. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
24. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
25. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
26. Double hit lymphoma: the MD Anderson Cancer Center clinical experience
27. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
28. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
29. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas
30. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
31. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma
32. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
33. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
34. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
35. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma
36. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
37. Thalidomide for patients with recurrent lymphoma
38. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
39. Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification
40. Detection of preferentialNRAS mutations in human male germ cell tumors by the polymerase chain reaction
41. Leukemic differentiation of a mediastinal germ cell tumor
42. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
43. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.